14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
AADR vs CASI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CASI Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 6–1 Matrix Metrics)
CASI Overall Winner
6-Pillar Tally: AADR 0 – 4 CASI (2 Tie)
Matrix Metrics: AADR 1 – 6 CASI
As of Nov 20, 2026, CASI Pharmaceuticals, Inc. (CASI) is the stronger overall head-to-head candidate over AdvisorShares Dorsey Wright (AADR) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AADR carries a Unified Composite Score of 39.4/100 (SELL) at $71.35 (N/M Forward P/E, N/A operating margin), whereas CASI carries 44.7/100 (HOLD) at $0.21 (N/M Forward P/E, -333.1% operating margin).
Technical & Structure Timing Caution: AADR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.7); meanwhile CASI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 18.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AADR vs CASI. Trailing 12-month operating profitability (AADR N/A vs CASI -333.1%) and valuation multiples (AADR N/M vs CASI N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
CASI Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $12.4M market capitalization and -333.1% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AADR vs CASI Key Questions & Quantitative Answers
As of Nov 20, 2026, CASI Pharmaceuticals, Inc. (CASI) is the stronger overall head-to-head candidate over AdvisorShares Dorsey Wright (AADR) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AADR carries a Unified Composite Score of 39.4/100 (SELL) at $71.35 (N/M Forward P/E, N/A operating margin), whereas CASI carries 44.7/100 (HOLD) at $0.21 (N/M Forward P/E, -333.1% operating margin). Technical & Structure Timing Caution: AADR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.7); meanwhile CASI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 18.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CASI leads the Growth & Scale pillar: AADR posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with CASI at -60.5% YoY revenue growth and +0.0% YoY earnings growth on $27M TTM revenue (35.8% gross margin, -333.1% operating margin). On trailing 12-month operating scale, AADR generates N/A in USD-normalized revenue versus $27M for CASI. In operating R&D and SG&A reinvestment, AADR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CASI.
CASI screens cheaper on headline valuation multiples. AADR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CASI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.5x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AADR (N/A ROE) versus CASI (-1094.5% ROE) capital efficiency.
In options market volatility and institutional positioning, AADR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.09β · 25% Vol realized risk). By comparison, CASI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.95β · 240% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.